CAR Bio Therapeutics

CAR Bio Therapeutics is a clinical-stage biotechnology company focused on the development of novel Chimeric Antigen Receptor (CAR) T-cell therapies specifically designed to treat solid tumors. The company was founded by Dr. Richard Junghans, a pioneer in the CAR-T field who was responsible for some of the earliest clinical trials of the technology. CAR Bio utilizes its proprietary Designer T Cell platform to engineer T cells that can better persist and function within the immunosuppressive environment of solid tumors. Its lead clinical program targets MUC1, a glycoprotein frequently overexpressed in breast and ovarian cancers. By translating decades of specialized research into clinical applications, the company aims to provide curative options for patients with advanced malignancies that are resistant to conventional therapies.